News

A new tuberculosis vaccine candidate, an innovative treatment for pregnant women living with HIV, a new treatment strategy for severe malaria in children, a promising treatment against multiple different parasitic worm infections, awareness-raising about female genital schistosomiasis.

From faster TB diagnosis and prevention to child-friendly malaria treatments, the new projects will develop innovative solutions to tackle critical infectious disease challenges.

Women remain under-represented in some areas of clinical research, and evidence gaps persist around the use of medicines and vaccines during pregnancy and breastfeeding. EDCTP3 is changing that.

Global Health EDCTP3 explains how collaborative research between Africa and Europe has helped address long-standing gaps in health care.

Global Health EDCTP3 invests €64 million to strengthen disease surveillance systems, train researchers and support faster responses to emerging health threats.

Global Health EDCTP3 received 60 applications by the 17 September 2026 deadline for the second stage of its 2026 calls, mobilising €113 million in pledged contributions.

Global Health EDCTP3 brings together governments, non-profits, pharmaceutical companies and others to tackle major health challenges.

Global Health EDCTP3 has received 38 applications for the EDCTP Prizes 2027, following the 24 September deadline, with submissions received across all seven prize categories.

Global Health EDCTP3 has received 243 applications by the 2 September deadline for the 2026 single-stage call. Applicants have requested nearly €491.7 million in Global Health EDCTP3 funding. The indicative available budget at call closure is €36.6 million.

Registrations are now open for participation in the EDCTP Forum 2027.